These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 14642395)

  • 1. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.
    Hasinoff BB; Patel D; Wu X
    Free Radic Biol Med; 2003 Dec; 35(11):1469-79. PubMed ID: 14642395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
    Barnabé N; Zastre JA; Venkataram S; Hasinoff BB
    Free Radic Biol Med; 2002 Jul; 33(2):266-75. PubMed ID: 12106822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
    Hasinoff BB; Patel D
    J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
    Hasinoff BB; Schroeder PE; Patel D
    Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
    Hasinoff BB
    Cardiovasc Toxicol; 2002; 2(2):111-8. PubMed ID: 12271154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
    Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
    Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum.
    Goudeau C; Loyevsky M; Kassim OO; Gordeuk VR; Nick H
    Br J Haematol; 2001 Dec; 115(4):918-23. PubMed ID: 11843826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.
    Jansová H; Macháček M; Wang Q; Hašková P; Jirkovská A; Potůčková E; Kielar F; Franz KJ; Simůnek T
    Free Radic Biol Med; 2014 Sep; 74():210-21. PubMed ID: 24992833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
    Malisza KL; Hasinoff BB
    Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
    Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
    Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.
    Hašková P; Koubková L; Vávrová A; Macková E; Hrušková K; Kovaříková P; Vávrová K; Simůnek T
    Toxicology; 2011 Nov; 289(2-3):122-31. PubMed ID: 21864640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
    Hasinoff BB; Patel D; Wu X
    Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICL670A: preclinical profile.
    Nick H; Wong A; Acklin P; Faller B; Jin Y; Lattmann R; Sergejew T; Hauffe S; Thomas H; Schnebli HP
    Adv Exp Med Biol; 2002; 509():185-203. PubMed ID: 12572995
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells.
    Malisza KL; Hasinoff BB
    Free Radic Biol Med; 1996; 20(7):905-14. PubMed ID: 8743977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.
    Arvapalli RK; Paturi S; Laurino JP; Katta A; Kakarla SK; Gadde MK; Wu M; Rice KM; Walker EM; Wehner P; Blough ER
    Cardiovasc Toxicol; 2010 Jun; 10(2):108-16. PubMed ID: 20229123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
    Kaiserová H; den Hartog GJ; Simůnek T; Schröterová L; Kvasnicková E; Bast A
    Br J Pharmacol; 2006 Dec; 149(7):920-30. PubMed ID: 17031387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
    Wu X; Patel D; Hasinoff BB
    J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
    Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
    Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.